Rising Demand for Weight Loss Drugs Raises Safety Concerns
Europe's drugs regulator, the European Medicines Agency (EMA), is conducting a review of weight-loss jabs, including Wegovy, Saxenda, and similar drugs, after being alerted to a possible link to thoughts of suicide and self-harm among users. The review was prompted by three cases reported in Iceland. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) will assess the risks of using weight-loss medication containing semaglutide or liraglutide. Suicidal thoughts are already listed as a possible side effect in product leaflets, but suicidal behavior is not currently listed. The EMA will communicate further findings as the review progresses.